THE IMPORTANCE OF DIFFERENTIATED IMMUNOCORRECTION IN THE TREATMENT OF BRONCHIECTASIS
Keywords:
bronchiectasis, respiratory infections, inflammation, immune response, immunological approachesAbstract
Bronchiectasis is characterized by a constant and abnormal expansion of the airways of the lungs (bronchi) and/or a violation of the tone of the muscle layer of the bronchial wall due to inflammation, sclerosis, dystrophy, hypoplasia. Bronchiectasis is a very common disease that is the main cause of respiratory problems. A deficiency in the host's immune response to bacterial infection is considered to be the main condition for the development of bronchiectasis. In addition, many patients have no identifiable cause and are defined as having an idiopathic disease. This can lead to the development of a chronic respiratory tract infection and subsequent inflammation. Patients tend to have persistent disease despite aggressive use of antibiotics and optimal sputum clearance techniques. New therapies based on the manipulation of the immune response are becoming available and offer significant promise for the treatment of this condition.
References
Ходош Э.М. Бронхоэктатическая болезнь: Учебное пособие для самостоятельной работы пульмонологов, торакальных хирургов, фтизиатров, терапевтов и врачей общей практики [Текст] / Э.М. Ходош. — Х., 2018. — 71 с.: ил.
Weycker D., Hansen G. L., Seifer F. D. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. Chronic Respiratory Disease. 2016;14(4):377–384.
Polverino E., Cacheris W., Spencer C., Operschall E. In O'Donnell AE: Global burden of non-cystic fibrosis bronchiectasis: A simple empidemiologic analysis. 2012.
Khikmatov, J. S., Khudaibergenov Sh. N., Khamdamov B. Z., Ismatov J. K. "Bronchiectasis (literature review)." Scientific progress 2.7 (2021): 94-108.
Weycker D, Edelsberg J, Oster G, Tino G. Prevalence and Economic Burden of Bronchiectasis. Clinical Pulmonary Medicine. 2005;12(4):205-209
Hikmatov J.S. "Bronchiectasis disease: etiology, pathogenesis, modern diagnosis and treatment." Новости образования: исследование в XXI веке 1.3 (2022): 1048-1064.
Martínez-García M. Á., Soler-Catalunã J. J., Sanz Y. D., et al. Factors associated with bronchiectasis in patients with COPD. CHEST. 2011;140(5):1130–1137.
King PT. The Role of the Immune Response in the Pathogenesis of Bronchiectasis. Biomed Res Int. 2018;2018:6802637.
King P. T., Sharma R., O'Sullivan K. M., et al. Deoxyribonuclease 1 reduces pathogenic effects of cigarette smoke exposure in the lung. Scientific Reports. 2017;7(1)
Chang A. B., Bell S. C., Torzillo P. J., et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Medical Journal of Australia. 2015;202(3):p. 130.
Polverino E., Goeminne P. C., McDonnell M. J., et al. European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal. 2017;50(3):p. 1700629.
Tarzi M. D., Grigoriadou S., Carr S. B., Kuitert L. M., Longhurst H. J. Clinical immunology review series: An approach to the management of pulmonary disease in primary antibody deficiency. Clinical & Experimental Immunology. 2009;155(2):147–155.
Stubbs A., Bangs C., Shillitoe B., et al. Bronchiectasis and deteriorating lung function in agammaglobulinaemia despite immunoglobulin replacement therapy. Clinical & Experimental Immunology. 2018;191(2):212–219.
Welsh E. J., Evans D. J., Fowler S. J., Spencer S. Interventions for bronchiectasis: an overview of Cochrane systematic reviews. Cochrane Database of Systematic Reviews. 2015;7:p. CD010337.
Serisier D. J., Martin M. L., McGuckin M. A., et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. Journal of the American Medical Association. 2013;309(12):1260–1267.
Hodge S., Tran H. B., Hamon R., et al. Nonantibiotic macrolides restore airway macrophage phagocytic function with potential anti-inflammatory effects in chronic lung diseases. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2017;312(5):L678–L687.
Polverino E., Rosales-Mayor E., Dale G. E., Dembowsky K., Torres A. The Role of Neutrophil Elastase Inhibitors in Lung Diseases. CHEST. 2017;152(2):249–262.
Konstan M. W., Ratjen F. Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis. Journal of Cystic Fibrosis. 2012;11(2):78–83.
O'Donnell A. E., Barker A. F., Ilowite J. S., Fick R. B. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. CHEST. 1998;113(5):1329–1334.
Brinkmann V., Zychlinsky A. Neutrophil extracellular traps: is immunity the second function of chromatin? The Journal of Cell Biology. 2012;198(5):773–783.
Yildirim I., Shea K. M., Pelton S. I. Pneumococcal disease in the era of pneumococcal conjugate vaccine. Infectious Disease Clinics of North America. 2015;29(4):679–697.
Pizzutto S. J., Yerkovich S. T., Upham J. W., Hales B. J., Thomas W. R., Chang A. B. Improving immunity to Haemophilus influenzae in children with chronic suppurative lung disease. Vaccine. 2015;33(2):321–326.
Khamdamov B. Z., Ganiev A. A., Khamdamov I. B. The role of cytokines in the immunopatogenesis of acute pancreatitis //Journal of Survey in Fisheries Sciences. – 2023. – Т. 10. – №. 2S. – С. 3949-3958.
Davlatov S. S., Khamdamov B. Z., Teshaev S. J. Neuropathic form of diabetic foot syndrome: etiology, pathogenesis, classifications and treatment (literature review) //Journal of Natural Remedies. – 2021. – Т. 22. – №. 1 (2). – С. 147-156.
